Profile data is unavailable for this security.
About the company
Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Company’s activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Company’s analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.
- Revenue in DKK (TTM)407.87m
- Net income in DKK136.28m
- Incorporated1997
- Employees173.00
- LocationChemometec A/SGydevang 43ALLEROED 3450DenmarkDNK
- Websitehttps://chemometec.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medistim ASA | 353.66m | 65.70m | 1.75bn | 152.00 | 26.67 | 6.69 | 21.43 | 4.96 | 5.55 | 5.55 | 29.87 | 22.12 | 1.13 | 0.7461 | 7.48 | 3,599,204.00 | 21.05 | 22.93 | 25.53 | 28.52 | 79.12 | 78.25 | 18.58 | 20.64 | 2.75 | -- | 0.0181 | 75.25 | 7.00 | 10.06 | -8.91 | 12.72 | 0.033 | 14.87 |
| CellaVision AB | 478.05m | 97.41m | 3.36bn | 228.00 | 34.46 | 6.74 | 26.98 | 7.02 | 6.30 | 6.30 | 30.91 | 32.19 | 0.7849 | 1.91 | 7.26 | 3,233,162.00 | 15.99 | 15.30 | 18.45 | 18.24 | 66.99 | 69.03 | 20.38 | 19.98 | 2.15 | 1,358.86 | 0.044 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
| RaySearch Laboratories AB (publ) | 758.10m | 113.52m | 3.45bn | 414.00 | 39.19 | 8.46 | 12.79 | 4.56 | 5.10 | 5.10 | 34.09 | 23.65 | 0.6023 | 5.51 | 3.29 | 3,005,152.00 | 9.02 | 1.29 | 13.69 | 1.88 | 91.06 | 90.57 | 14.97 | 2.55 | 1.27 | 108.61 | 0.3706 | 69.00 | 21.16 | 10.26 | 243.06 | 0.7648 | -1.31 | -- |
| Surgical Science Sweden AB | 557.60m | 125.38m | 4.83bn | 270.00 | 38.56 | 1.68 | 29.62 | 8.67 | 3.79 | 3.79 | 16.85 | 87.19 | 0.1769 | 1.56 | 6.80 | 3,307,035.00 | 3.98 | 4.49 | 4.21 | 4.78 | 68.65 | 70.06 | 22.49 | 23.75 | 3.73 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Revenio Group Oyj | 761.18m | 141.75m | 5.37bn | 230.00 | 37.48 | 7.10 | 29.70 | 7.06 | 0.7204 | 0.7204 | 3.86 | 3.81 | 0.7834 | 4.93 | 8.17 | 472,574.10 | 14.67 | 14.33 | 17.09 | 17.90 | 49.29 | 50.73 | 18.72 | 21.13 | 1.51 | 34.57 | 0.1276 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Arjo AB (publ) | 7.25bn | 331.38m | 5.47bn | 6.85k | 17.69 | 1.15 | 5.63 | 0.7541 | 1.88 | 1.88 | 41.05 | 28.87 | 0.7149 | 4.54 | 6.78 | 1,644,896.00 | 3.26 | 3.55 | 4.62 | 5.55 | 43.64 | 44.01 | 4.56 | 5.41 | 0.626 | 3.97 | 0.4073 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Biotage AB | 1.38bn | 166.66m | 8.05bn | 675.00 | 48.29 | 3.26 | 28.33 | 5.83 | 3.21 | 3.21 | 26.56 | 47.60 | 0.4312 | 1.59 | 7.22 | 3,155,786.00 | 5.21 | 10.74 | 6.05 | 12.77 | 62.67 | 61.40 | 12.08 | 15.75 | 1.15 | 43.88 | 0.0616 | 40.11 | 19.54 | 15.50 | -8.21 | 7.97 | 14.05 | 1.30 |
| ChemoMetec A/S | 407.87m | 136.28m | 8.22bn | 173.00 | 60.32 | 14.54 | 53.38 | 20.16 | 7.83 | 7.83 | 23.44 | 32.48 | 0.6112 | 0.745 | 6.97 | 2,357,630.00 | 20.42 | 27.96 | 24.40 | 35.10 | 78.80 | 79.57 | 33.41 | 35.02 | 3.76 | -- | 0.0073 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
| Xvivo Perfusion AB | 486.76m | 132.47m | 9.22bn | 161.00 | 68.63 | 6.83 | 51.53 | 18.95 | 6.58 | 6.58 | 24.07 | 66.13 | 0.3325 | 1.14 | 4.67 | 4,691,194.00 | 9.05 | 1.24 | 9.68 | 1.33 | 74.41 | 73.14 | 27.21 | 4.76 | 4.23 | -- | 0.0117 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| AddLife AB | 6.49bn | 75.87m | 10.09bn | 2.36k | 137.49 | 3.14 | 14.83 | 1.55 | 0.9601 | 0.9601 | 82.16 | 42.09 | 0.7625 | 3.50 | 5.58 | 4,351,152.00 | 0.9063 | 5.31 | 1.29 | 8.83 | 37.30 | 36.89 | 1.19 | 5.79 | 0.638 | 1.66 | 0.5146 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| Elekta AB (publ) | 11.75bn | 734.75m | 15.08bn | 4.57k | 21.30 | 2.25 | 10.07 | 1.28 | 2.96 | 2.96 | 47.38 | 28.01 | 0.5822 | 3.16 | 2.89 | 3,903,469.00 | 3.65 | 4.19 | 6.53 | 7.51 | 36.76 | 39.03 | 6.27 | 7.37 | 0.7425 | 3.91 | 0.4196 | 68.60 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Embla Medical hf | 6.01bn | 494.30m | 15.43bn | 4.00k | 31.42 | 2.75 | 17.45 | 2.57 | 1.15 | 1.15 | 13.95 | 13.13 | 0.5755 | 2.23 | 6.65 | 1,503,869.00 | 4.75 | 4.06 | 5.51 | 4.76 | 62.02 | 62.47 | 8.25 | 6.91 | 1.26 | 6.59 | 0.4074 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Vitrolife AB | 2.30bn | -2.47bn | 19.45bn | 1.10k | -- | 2.28 | -- | 8.44 | -28.10 | -28.10 | 26.24 | 97.03 | 0.1867 | 3.48 | 6.48 | 3,293,791.00 | -19.99 | -4.57 | -20.71 | -4.78 | 58.16 | 58.38 | -107.03 | -21.89 | 2.36 | 9.24 | 0.135 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
Data as of Nov 25 2024. Currency figures normalised to Chemometec A/S's reporting currency: Danish Krone DKK
38.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 21 Nov 2024 | 1.66m | 9.55% |
| Invesco Advisers, Inc.as of 16 May 2023 | 881.14k | 5.06% |
| Fj�rde AP-fondenas of 30 Jun 2024 | 597.30k | 3.43% |
| SEB Investment Management AB (Denmark)as of 31 Oct 2024 | 582.40k | 3.35% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 558.12k | 3.21% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 525.64k | 3.02% |
| Swedbank Robur Fonder ABas of 31 Oct 2024 | 525.00k | 3.02% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 30 Aug 2024 | 512.29k | 2.94% |
| SEB Investment Management ABas of 31 Oct 2024 | 461.95k | 2.66% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 420.88k | 2.42% |
More ▼
Data from 30 Aug 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
